Benitec Biopharma Limited

Biomics Biotechnologies, Co., Ltd.

Biocross Institute of Molecular Medicine (nantong) Co., Ltd.

YiXiang Lu

YunCheng Sun

York YuanYuan Zhu

Michael Wayne Graham

Tiejun Li

Peter French

XiaoJun Tang

Li Shan

Jinkang Wang

TieJun Li

Li Chen

York Yuan Yuan Zhu

Xiaojun Tang

This invention is directed to a RNA interference (RNAi) agent and the use of that RNAi agent to treat hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, where the agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some forms of the invention, the agent has more than one effector sequence. Multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

HBV treatment

RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

This invention relates to the application of the highly conserved sequences of viral genome, especially from a highly conserved domain of enteroviral genome as templates to design target small ligand RNAs (sliRNAs). The resulting sliRNAs are therapeutically active ingredients in the treatment of the related diseases caused by pathological angiogenesis.

Application of highly conserved domain sequences from viral genome as template to design therapeutic sliRNAs

Application of highly conserved domain sequences from viral genome as template to design therapeutic slirnas

Growing community of inventors

Nantong, China

YiXiang Lu